APA Zitierstil

Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., . . . Muntoni, F. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet Publishing Group.

Chicago Zitierstil

Cirak, Sebahattin, et al. Exon Skipping and Dystrophin Restoration in Patients With Duchenne Muscular Dystrophy After Systemic Phosphorodiamidate Morpholino Oligomer Treatment: An Open-label, Phase 2, Dose-escalation Study. Lancet Publishing Group, 2011.

MLA Zitierstil

Cirak, Sebahattin, et al. Exon Skipping and Dystrophin Restoration in Patients With Duchenne Muscular Dystrophy After Systemic Phosphorodiamidate Morpholino Oligomer Treatment: An Open-label, Phase 2, Dose-escalation Study. Lancet Publishing Group, 2011.

Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.